✨ Free AI Report
Sequana Medical NV: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sequana Medical NV
Company Research

Sequana Medical NV: Business Overview, Financials & Competitive Analysis

Sequana Medical NV scores 6/10 on the AskCyborg Cyborg Score (Solid). Promising medtech disruptor addressing large unmet need in drug-resistant fluid overload, but execution risk remains high until scaled commercial adoption demonstrates sustainable unit economics. Sequana Medical demonstrates solid fundamentals with FDA approval for alfapump, strong clinical efficacy, and early US commercial traction. However, the company remains early-stage in revenue.

What is Sequana Medical NV's industry? Sequana Medical NV (sequanamedical.com) operates in Medical Devices - Cardiovascular and Hepatology Therapeutics. AskCyborg classifies Sequana Medical NV under Medical Devices - Cardiovascular and Hepatology Therapeutics in its company registry.

Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer. The company commercializes the alfapump®, an implantable device approved by FDA, and Direct So...

6/ 10Solid

Cyborg Score thesis

Promising medtech disruptor addressing large unmet need in drug-resistant fluid overload, but execution risk remains high until...

Read the full analyst-debate transcript →
Industry Medical Devices - Cardiovascular and Hepatology Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Sequana Medical NV Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Sequana Medical NV

AskCyborg analysts argue the bull and bear cases for Sequana Medical NV across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Sequana Medical NV OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Sequana Medical NV Overview

Pro stress-test →

Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer. The company commercializes the alfapump®, an implantable device approved by FDA, and Direct Sodium Removal (DSR) technology, targeting a significant unmet medical need in patients where standard diuretics are ineffective.

Strategic Profile

Pro stress-test →

Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. The company announced strong commercial US progress with implants of the alfapump® System having been completed at five leading centers since launch in Q4 2025. The medtech company operates in a specialized niche with proprietary technology and clinical evidence supporting premium market positioning.

Competitive Landscape

Pro stress-test →

Sequana Medical operates in the specialized medtech space for fluid management with limited direct competitors offering implantable solutions. Competitors in broader interventional cardiology and fluid management include companies like Endologix, though alfapump's proprietary design and clinical evidence provide differentiation. The company focuses on a specific high-acuity patient population underserved by pharmaceutical approaches.

Industry Context

Sequana Medical NV operates in Medical Devices - Cardiovascular and Hepatology Therapeutics.

Key facts

Founded: 2006 · Headquarters: Ghent, Belgium · Employees: 48 · Revenue: $0.106M · Market cap: $50.9M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Sequana Medical NV.

  • FDA breakthrough designation and approval for alfapump addresses significant unmet need with 100% median reduction in therapeutic paracentesis in pivotal POSEIDON trial
  • Dual-technology platform (alfapump and DSR) provides multiple market entry points across liver disease, malignant ascites, and heart failure indications
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Announced strong US commercial progress with alfapump implants at five leading centers since Q4 2025 launch
  • January 2026Completed €62M share placement for capital to fund growth initiatives
  • +2 moreTrack every material event for Sequana Medical NV as it happens. Explore monitoring →
Get alerted when Sequana Medical NV has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Peritoneal Dialysis SolutionsTraditional fluid removal approach for end-stage renal disease→Ultrafiltration DevicesHeart failure fluid management via hemofiltration→Interventional CardiologyVascular intervention and fluid management devices→

Compare Sequana Medical NV with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sequana Medical NV operates in Medical Devices - Cardiovascular and Hepatology Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Cardiovascular and Hepatology Therapeutics research →
NEW · MCP server

Ask your AI assistant about Sequana Medical NV

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sequana Medical NV and its top competitor on Cyborg Score”
“What did Sequana Medical NV do this quarter?”
“Is Sequana Medical NV a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Sequana Medical NV do?+
Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer. The company commercializes the alfapump®, an implantable device approved by FDA, and Direct So...
What is Sequana Medical NV's Cyborg Score?+
Sequana Medical NV has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sequana Medical NV's main competitors?+
Named competitors include Peritoneal Dialysis Solutions, Ultrafiltration Devices, Interventional Cardiology. The full competitive landscape is in the AskCyborg report.
How can I get the full Sequana Medical NV research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sequana Medical NV research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sequana Medical NV over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.